Related by context. All words. (Click for frequent words.) 67 Receives Approvable Letter 67 Announces Tentative Approval 67 Submits NDA 67 Files Investigational 64 FDA Accepts 63 Submits Supplemental 63 Submits Investigational 63 Release Tablets 63 Submits Biologics License Application 63 Mylan Receives Approval 62 Supplemental Biologics License Application 62 Completes Patient Enrollment 62 submitted supplemental Biologics 61 Receives Orphan Drug Designation 61 submitted Biologics License 61 XL# anticancer compounds 60 Submits Response 60 highly purified pasteurized 60 Levoleucovorin 60 Granted Orphan Drug 60 Investigational Compound 60 Focalin XR ® 60 vapreotide acetate 60 Meets Primary Endpoint 59 Resubmission 59 methylnaltrexone bromide 59 depressive episodes associated 59 mesylate tablets approved 59 Biological License Application 59 Extended Release Capsules 59 Phase 2a Trial 59 Horizant ™ 59 Tesamorelin 59 Application BLA 59 Marketing Approval PMA 58 KRYSTEXXA TM pegloticase 58 markets HP Acthar 58 Marketing Authorisation Application 58 corticotropin injection 58 granted Ortec 58 Metformin HCl 58 Testosterone Gel 58 TRANSDUR ® 58 hydrochloride tablets 58 pralatrexate injection folate analogue 57 NDA Submission 57 BRILINTA 57 Tezampanel 57 PROVENGE ® 57 topical gel formulation 57 FDA Approvable Letter 57 Phase IIb Trial 57 Oral Calcitonin 57 Application MAA 57 novel trazodone formulation 57 Initiates Phase II 57 Orapred ODT 57 Initiate Clinical Trial 57 Initiates Phase III 57 SinuNase ™ 57 Renvela ® 57 proprietary intravenous formulation 57 Morphine Sulfate 56 FUSILEV ® 56 liver resection surgeries 56 vinorelbine emulsion 56 License Application sBLA 56 REMOXY NDA 56 NUEDEXTA ™ 56 Marketing Authorisation Application MAA 56 Surgical Adhesive 56 Study Evaluating 56 Phase III Trial 56 IND Application 56 Ropinirole 56 nasal calcitonin product 56 Phase III Clinical Trial 56 FACTIVE R gemifloxacin 56 ANDA containing 56 RANK Ligand inhibitor 56 rasagiline tablets 56 Abstral ® 56 Risperidone Oral Solution 56 BioGlue R 56 Trelstar R 55 Extended Release 55 Fast Track Status 55 LymphoStat B belimumab 55 ULTRASE 55 ONSOLIS TM 55 Patient Enrollment 55 TAXUS Element Stent System 55 generation purine nucleoside 55 allosteric modulator PAM 55 NEBIDO R 55 KRYSTEXXA TM 55 Premarket Approval Application 55 Release Capsules 55 sNDAs 55 ® decitabine 55 Amigal TM 55 Extended Release Tablets 55 VIVITROL ® 55 CIP TRAMADOL ER 55 miconazole Lauriad ® 55 sapropterin dihydrochloride 55 Kuvan TM sapropterin 55 Keppra ® XR 55 Personalized Immunotherapy 55 Transdermal System 55 ELADUR ™ 55 SYCREST 55 Inhalation Aerosol 55 VISICOL R 55 dihydrochloride Tablets 55 dextromethorphan quinidine 55 Divalproex Sodium 55 PDUFA Date 54 Orally Disintegrating Tablets 54 vinorelbine tartrate 54 Kuvan R 54 Febuxostat 54 Zorbtive TM 54 fluvoxamine maleate 54 balsalazide tablet 54 Femring ® 54 Biologic License Application 54 virus HCV protease inhibitor 54 Somatuline Depot 54 Phase IIb Clinical Trial 54 R Saizen R 54 BEMA TM LA 54 ZEGERID Chewable Tablets 54 Act PDUFA date 54 CIMZIA r 54 solifenacin succinate 54 Transcept Pharmaceuticals 54 ferumoxytol Injection 54 ibuprofen Injection 54 Solzira TM 54 Oral Solution 54 oral prodrug 54 Mometasone Furoate 54 Drug Applications ANDAs 54 Empatic TM 54 POSIDUR TM ELADUR TM 54 PREOS R 54 DIFICID ™ 54 diarrhea predominant irritable 54 LEVADEX TM 54 Lenocta TM 54 Silenor ® doxepin 53 By JAMAAL ABDUL 53 Bazedoxifene 53 5 lipoxygenase inhibitor 53 sevelamer carbonate 53 Inc. NASDAQ HITK 53 FDA Complete Response 53 refractory chronic lymphocytic 53 Fast Track designations 53 Ranexa R 53 sterile lidocaine patch 53 HP Acthar Gel repository 53 Benazepril 53 LymphoStat B TM 53 Inc. Nasdaq SEPR 53 PNP inhibitor 53 POSIDUR TM 53 topical non steroidal 53 Zolpimist 53 NASDAQ BDSI 53 Ciclesonide 53 Gel repository corticotropin injection 53 Iluvien ® 53 Celgene Thalomid 53 non nucleoside inhibitor 53 Zenvia ™ 53 Biologic License Application BLA 53 FDA approvable letter 53 Dexilant 53 Kristalose ® lactulose 53 Pruvel 53 Initiate Phase 53 Xenazine ® 53 Panzem R 53 mesylate tablets 53 PROMUS Element Stent System 53 ZEGERID Capsules 53 OMAPRO ™ 53 Phase 2b Trial 53 application sNDA 53 norepinephrine reuptake inhibitor 52 ZALBIN 52 Pivotal Phase III 52 testosterone gel LibiGel 52 VALSTAR R 52 Pegloticase 52 sBLA 52 albiglutide 52 Complete Response 52 GATTEX TM 52 ACUROX ® 52 PDE4 inhibitor 52 Emezine 52 Drug Application 52 Xcytrin R 52 Zavesca r 52 lexidronam injection 52 APF# NDA 52 overactive bladder AA# 52 Anturol TM 52 Archexin 52 ILUVIEN ® 52 Valtropin 52 Soriatane 52 FOLOTYN ® 52 pantoprazole sodium 52 NYSE Amex PTN 52 NasdaqGM NTEC today 52 Fortical R 52 Somatuline R Autogel R 52 Testosterone MDTS ® 52 Investigational Treatment 52 Trobalt 52 granulated mesalamine 52 Nitoman 52 BYETTA ® 52 Market Approval PMA 52 supplemental biologics 52 inhaled formulation 52 FDA Approval 52 pioglitazone HCl 52 ALVESCO R 52 morphine sulfate extended 52 Dyloject TM 52 Metformin GR 52 zolpidem tartrate sublingual tablet 52 ABILIFY ® 52 CIP ISOTRETINOIN 51 ATPace TM 51 Evoltra ® 51 Complete Response letter 51 Elagolix 51 ENZON 51 Tramadol ER 51 IV APAP 51 Marketing Authorization Application MAA 51 XIAFLEX ® 51 ALN PCS 51 Xibrom TM 51 ABILIFY R 51 LSE SHP NASDAQ SHPGY 51 Aloxi ® 51 SUMAVEL 51 Durezol TM 51 Pivotal Phase 51 HFA MDI 51 serotonin norepinephrine reuptake inhibitor 51 AMRIX 51 Nabi HB Intravenous 51 levocetirizine 51 autologous cellular immunotherapy 51 Oracea TM 51 Product Monograph 51 Acetavance TM 51 New Drug Application 51 Omigard TM 51 Pivotal Trial 51 Emezine R 51 ZEVALIN ® 51 Preotact 51 nephropathic cystinosis cystinosis 51 Loramyc R 51 RECOTHROM R 51 T Pred 51 intranasal formulation 51 Exocrine Pancreatic Insufficiency 51 ZEGERID Powder 51 Saforis 51 NESINA 51 SinuNase TM 51 LEVADEX ™ 51 supplemental Biologics License Application 51 Kamada AAT 51 submit Biologics License 51 Drug Application ANDA 51 generation PNP inhibitor 51 Drug Eluting Stent System 51 VALSTAR 51 DAYTRANA TM 50 cinacalcet HCl 50 Phase III Pivotal 50 initiate Phase IIb 50 NitroMist TM 50 Nasdaq DVAX 50 Combunox 50 EvaMist TM 50 Nerve Targeting Drug 50 Auxilium Pharma 50 Sanctura XR 50 Liprotamase 50 treat male hypogonadism 50 Orphan Drug Status 50 ORENCIA ® 50 SILENOR 50 Orphan Drug designations 50 Panzem R NCD 50 investigational atypical antipsychotic 50 intravenous acetaminophen 50 Stavzor 50 Cleviprex TM clevidipine 50 StaphVAX R 50 OMNARIS HFA 50 mGluR5 negative 50 Frova ® 50 Ixempra 50 human C1 inhibitor 50 ATPace 50 Inc. Nasdaq VVUS 50 Uvidem 50 proprietary transdermal patch 50 tiapamil 50 Avanafil 50 Ambrisentan 50 topically applied SEPA 50 Cefprozil 50 TELINTRA 50 IONSYS TM 50 individualized cellular immunotherapy 50 Zingo TM 50 Impax ANDA 50 reliever tramadol 50 Zenpep 50 PhosLo R 50 QNEXA 50 sNDA 50 Luveniq 50 oxymorphone ER 50 formerly LymphoStat B 50 Enjuvia 50 Actonel ® 50 XOPENEX HFA MDI 50 RELISTOR ® 50 subcutaneous RELISTOR 50 Iloperidone 50 Civacir 49 IIa trial 49 Friedreich Ataxia FRDA 49 NASDAQ SHPGY 49 Serdaxin ® 49 Contrave NDA 49 octreotide acetate 49 Exalgo TM 49 Velaglucerase Alfa 49 Xyzal R 49 Strativa 49 Ereska 49 hoFH 49 Sanvar R 49 Ketotransdel 49 Zenvia TM 49 Biologics License Application 49 ACUROX 49 acyclovir Lauriad R 49 FIRAZYR 49 NVA# 49 BEMA TM Fentanyl 49 Lixisenatide 49 Premarket Approval PMA 49 Gestiva TM 49 Milnacipran 49 sNDA submission 49 Marketing Authorization Application 49 investigational humanized monoclonal antibody 49 Thelin TM 49 Sycrest 49 Anturol ® 49 Ferumoxytol 49 IV acetaminophen 49 Orphan Drug designation 49 Plicera 49 Pirfenidone 49 Intermezzo ® NDA 49 ENTEREG ® 49 SUPPRELIN R LA 49 Preotact R 49 Ceflatonin R 49 GRAS notification 49 Efficacy Results 49 lucinactant 49 faropenem medoxomil 48 Requip XL 48 JOULFERON 48 LUCASSIN 48 AzaSite Plus 48 TSX SHQ 48 Evoltra R 48 Drug Submission 48 ORENCIA R 48 Fast Track Designation 48 AMITIZA R 48 Flutiform ™ 48 KALBITOR ® 48 ELADUR 48 Acurox r Tablets 48 OLpur TM H2H 48 Investigational Device Exemption 48 Daytrana ® 48 Evamist TM 48 miconazole Lauriad R 48 Orathecin 48 Actemra tocilizumab 48 Alvesco R 48 OMNARIS 48 severe hypercholesterolemia 48 Zensana 48 diabetic peripheral neuropathic DPN 48 Nascobal Nasal Spray 48 Onalta 48 MNTX 48 REMOXY R 48 Nexavar ® 48 Silenor ® 48 AMITIZA ® 48 Ketotransdel TM 48 BLA filing 48 Ramelteon 48 Approvable Letter 48 PrevOnco ™ 48 XIAFLEX ™ 48 Lubiprostone 48 Aloxi Injection 48 Oracea ® 48 ONSOLIS 48 TRANSDUR TM Sufentanil 48 Mutual Recognition Procedure 48 Prestara TM 48 postherpetic neuralgia PHN 48 k premarket 48 Marketing Authorization 48 Phase 1b trial 48 cutaneous T 48 brand eszopiclone 47 sublingual tablets 47 NitroMist 47 XIBROM 47 Icatibant 47 TRANSDUR Sufentanil 47 Cellegesic 47 Fanapt TM 47 Arzerra ofatumumab 47 Vion Pharmaceuticals 47 Oral Suspension 47 NASDAQ CXSP announced 47 pseudobulbar affect PBA 47 Cutanea Life Sciences 47 Marketing Authorization Applications 47 Onco TCS 47 IL# PE#QQR 47 topical NSAID 47 Vernakalant 47 Aryplase 47 Inhalation Solution 47 ISO Vorin TM 47 Xolegel 47 REPLAGAL 47 Simulect 47 Phase III Clinical Trials 47 Vilazodone 47 Raptiva R 47 Clofarabine 47 Cetrorelix 47 Xyrem ® 47 GENERIC SILDENAFIL SOFT Generic 47 Entereg R 47 Fanapt ™ 47 ANDA submission 47 Exalgo 47 Orphan Drug status 47 Junovan TM 47 ONCONASE R 47 SUTENT ® 47 Glybera R 47 Drug Administration FDA Oncologic 47 REMOXY ® 47 ATryn ® 47 Soliris eculizumab 47 Diabetic Macular Edema 47 ANDAs 47 Abbott Laboratories Depakote 47 Onyx Pharma 47 lorcaserin NDA 47 LUNESTA TM 47 Market Authorization Application 47 Biologics License Application BLA 47 Entereg TM 47 MONOVISC 47 TYGACIL 47 HCV protease inhibitor 47 Fibrillex TM 47 indiplon capsules 47 Pennsaid R 47 Dalbavancin 47 LibiGel ® 47 Fortigel 47 Genasense ® oblimersen 46 Indaflex TM 46 GEM #S 46 MAA submission 46 Sanctura 46 Octreolin 46 Viviant 46 Velac 46 octreotide implant 46 ONTAK 46 Ustekinumab 46 Clinical Trial Application 46 Cobalt Pharmaceuticals 46 DPP4 inhibitor 46 JAK inhibitor 46 CDP# 46 Loramyc 46 STEDESA 46 elotuzumab 46 SILENOR ™ 46 Asmanex 46 THALOMID 46 Frova R 46 LUVOX CR 46 silodosin 46 Onsolis 46 IND Investigational New 46 Stavzor ™ 46 Complete Response Letter 46 Linjeta TM 46 Phase 1a clinical 46 Orphan Therapeutics 46 Oral Suspension #mg 46 Firdapse 46 PLK1 SNALP 46 Phase IIb trials 46 commercialize toremifene 46 Approvable letter 46 Orphan Drug Designation 46 dalbavancin 46 ONGLYZA ™ 46 Troxatyl 46 Oracea 46 BENLYSTA ® 46 Rapinyl 46 SILENOR TM 46 prokinetic agent 46 prodrug stimulant 46 Luvox CR 46 OLEPTRO TM 46 registrational trial 46 injectable formulation 46 Solzira 46 QRxPharma 46 Reloxin ® 45 Cimzia TM 45 CRMD# 45 Inc. NASDAQ AVNR 45 Fentanyl Taifun 45 mometasone furoate 45 subcutaneously administered 45 ruxolitinib 45 PHX# 45 BEMA Buprenorphine 45 PDX pralatrexate 45 Hematide ™ peginesatide 45 ATryn R 45 Guanilib 45 Xibrom QD 45 methylnaltrexone 45 oral hydromorphone 45 Keppra ® levetiracetam 45 diabetic peripheral neuropathic pain 45 sNDA filing 45 ANDA 45 diabetic neuropathic pain 45 post herpetic neuralgia PHN 45 Clevudine 45 RSD# 45 Relistor 45 DU #b 45 oral methylnaltrexone 45 Palatin Technologies Inc. 45 PMA submission 45 Phase Ib study 45 histone deacetylase HDAC inhibitor 45 Prestara 45 torezolid phosphate 45 Abbreviated New 45 humanized anti 45 Zyflo 45 formoterol fumarate 45 Omigard 45 Vimovo 45 Flutiform TM 45 PMA Supplement 45 Nasdaq VRTX 45 alogliptin 45 zileuton CR 45 Neurodex 45 Ruconest 44 GLP toxicology studies 44 LibiGel NDA 44 MK #B 44 taliglucerase alfa 44 Tolvaptan 44 Phase IIa clinical trials 44 Oporia 44 UPLYSO 44 BLOOM DM 44 IND submission 44 Soliris TM eculizumab 44 Roflumilast 44 NASDAQ IMCL 44 novel bactericidal 44 Raptiva ® 44 desvenlafaxine 44 apaziquone 44 Rectogesic 44 initiate Phase IIa 44 Joulferon 44 Investigational Device Exemption IDE 44 trospium 44 Fodosine 44 SNT MC# 44 omeprazole sodium bicarbonate 44 subcutaneous formulation 44 Humanitarian Device Exemption 44 ACOMPLIA R 44 Dacogen injection 44 Junovan 44 Esbriet pirfenidone 44 Functional Dyspepsia 44 orphan designation 44 tetrabenazine 44 ARCOXIA 44 eprodisate KIACTA TM 44 Corlux 44 gabapentin enacarbil 44 Rhucin R 44 Firazyr 44 gepirone ER 44 oral ridaforolimus 44 Opana ER 44 EMBEDA ™ 44 Lodotra 44 cell lymphoma CTCL 44 phase IIb clinical 44 tafamidis 43 Abstral 43 alvimopan 43 OFIRMEV 43 diabetic macular edema DME 43 Zelrix 43 REVLIMID lenalidomide 43 Surfaxin LS 43 TachoSil 43 QAB# indacaterol 43 severe gastroparesis 43 phase IIb trial 43 pancreatic insufficiency 43 inhaled liposomal ciprofloxacin 43 BCX# 43 non constipation irritable 43 Vitaros 43 refractory Hodgkin lymphoma 43 exocrine pancreatic insufficiency 43 teduglutide 43 Zenvia Phase III 43 Premarket Approval 43 SUCCEED trial 43 Augment Bone Graft 43 Ketotransdel ® 43 DDP# 43 Jevtana 43 METOZOLV ODT 43 FUSILEV 43 Nebido 43 Fx #A 43 LEUKINE 43 Urocidin 43 PRX # 43 SEROQUEL XR 43 ANTEGREN 43 Aerosurf 43 Priority Review 43 bicifadine 43 Cimzia ® 43 BENLYSTA 43 Drug Submission NDS 43 ADVEXIN p# therapy 43 Alogliptin 43 vinflunine 43 BLA submission 43 Silenor NDA 43 TREANDA 43 LIALDA 42 Sular formulation 42 Augment Injectable 42 tezampanel 42 BEMA Fentanyl 42 Rescula 42 Bifeprunox 42 LUVENIQ 42 Satraplatin 42 Neuromodulation System 42 EMBEDA 42 Acetavance 42 PDUFA date 42 Preos 42 telavancin NDA 42 PRISTIQ 42 atypical antipsychotic medication 42 Camvia 42 Lung Rx 42 Q#IR 42 % uracil topical 42 Plenaxis TM 42 tolevamer 42 ITAX 42 GALNS 42 acyclovir Lauriad ® 42 iloperidone 42 forodesine 42 Celsion Corporation 42 initiate Phase Ib 42 SPARLON 42 Proxinium TM 42 European Medicines Evaluation 42 NDA resubmission 42 Phase IIa trial 42 Phenoptin 42 Phase IIIb clinical 42 confirmatory Phase 3 42 Alzhemed TM 42 Amoxicillin PULSYS 42 MethyPatch 42 Apricus Bio 42 bazedoxifene 42 Phase 1b clinical 42 vernakalant oral 42 AeroLEF TM 42 APF# 42 NDA submission 42 Telavancin 42 Dupuytren Contracture 42 dose escalation clinical 42 Renvela 42 Phase IIa trials 42 Phase IIb clinical trials 42 Vasovist 42 naproxen esomeprazole magnesium 42 CHMP recommendation 42 diquafosol tetrasodium 42 NEBIDO 42 paliperidone palmitate 42 investigational compound 42 intravenous formulation 42 Neurodex TM 41 ofatumumab HuMax CD# 41 ketoprofen patch 41 CoFactor 41 prGCD 41 EGRIFTA TM 41 Fast Track designation 41 peginesatide 41 eltrombopag 41 Gabapentin GR 41 Tolevamer 41 Orphan Drug 41 Indiplon 41 approvable letter 41 aclidinium bromide 41 Dyloject 41 post operative ileus 41 vernakalant hydrochloride 41 MHLW 41 NUVIGIL 41 daily tramadol 41 ENRICH trial 41 Aurexis 41 IND enabling 41 Onrigin TM 41 NGX# 41 DC Bead 41 Evoltra 41 Mepact 41 NovaDel 41 Genz # 41 candidate Zentase 41 Anturol 41 CINTREDEKIN BESUDOTOX 41 IPLEX 41 PEG PAL 41 L DOS# 40 regadenoson 40 cutaneous T cell 40 postoperative ileus POI 40 Phase 2b study 40 JZP 6 40 Onrigin 40 oral calcitonin 40 SparVax TM 40 XiDay 40 Voraxaze 40 Phase 2a clinical 40 lomitapide 40 BROMDAY 40 fostamatinib 40 Sumavel DosePro 40 resubmission 40 PREOS 40 vilazodone 40 Adcirca 40 Daytrana TM 40 Investigational 40 PEG INTRON 40 Ventavis 40 phase IIa clinical 40 Cinryze TM 40 Pennsaid 40 Biologics Licensing 40 Zalbin 40 chronic idiopathic thrombocytopenic purpura 40 oral cladribine 40 Firazyr ® 40 ONCONASE 40 Intermezzo ® 40 Trexima 40 Kynapid 40 OROS R Hydromorphone 40 confirmatory Phase III 40 Phase 2b trial 40 Sucampo 40 Enablex 40 Act PDUFA 40 EOquin 40 FavId 40 Phase Ib 40 Cloretazine R VNP#M 40 approvable letters 39 dirucotide MBP# 39 initiate Phase 1b 39 HZT 39 dirucotide 39 orally administered 39 PhosLo 39 Itopride 39 topical gel 39 ezogabine 39 DASISION 39 brentuximab 39 Jerini 39 phase IIb 39 transdermal patch 39 carcinogenicity studies 39 Pixuvri 39 Rhucin ® 39 phase 2a 39 BYDUREON 39 Orazol 39 amifampridine phosphate 39 refractory APL 39 PIX# trial 39 MOZOBIL 39 New Drug IND 39 phase IIa 39 Ofirmev 39 faropenem 39 Zenvia 39 Sancuso 39 Phase 2a trial 39 eprodisate Fibrillex TM 39 ELAPRASE 39 pharmacokinetic studies 39 mifamurtide 39 Phase 1b 39 milnacipran 38 Marqibo 38 fidaxomicin 38 AeroLEF 38 Exelbine 38 Phase Ia 38 ocular hypertension 38 Dextofisopam 38 Cladribine Tablets 38 initiate Phase 38 clofarabine 38 linaclotide 38 Shionogi 38 Intermezzo R 38 Dacogen 38 albinterferon alfa 2b 38 Neupro ® 38 Horizant 38 Iluvien 38 tasimelteon 38 NOXAFIL 38 RELISTOR 38 Phase IIB 38 lubiprostone 38 ThermoDox ® 38 Seroquel XR 38 ecallantide 38 Phase III pivotal 38 INCB# [002] 38 tramiprosate ALZHEMED TM 38 multiple ascending dose 38 Inc. OTCBB SYBD 37 Qutenza 37 Topical Interferon Alpha 2b 37 CORLUX 37 registrational 37 FOSRENOL 37 Amitiza 37 bifeprunox 37 CEQ# 37 pralatrexate 37 Phase IIa clinical 37 Phase IIb clinical 37 Phase 2a 37 Phase III clinical trials 37 satraplatin 37 velaglucerase alfa 36 palifosfamide 36 Zerenex 36 ADVEXIN 36 Promacta 36 Kuvan 36 EpiCept 36 Phase 2b 36 pivotal Phase III 36 GATTEX 36 BioMimetic 36 Ceplene 36 Clolar 36 MBP# [001] 36 & JPRD 36 carcinogenicity study 36 VYVANSE 36 Riquent 36 Entereg 36 Human Genetic Therapies 36 LEVADEX 36 Flutiform 36 IND 35 INDs 35 liprotamase 35 Special Protocol Assessment 35 Gencaro 35 Rhucin 35 Phase 2b clinical 35 CHMP 35 naproxcinod 35 KRYSTEXXA 35 Trizytek 35 Drug Administration FDA 35 Phase IIa 35 Phase IIb trial 35 Phase III clinical 35 orphan drug 35 Exelbine NDA 35 Phase II 35 XIAFLEX 35 pegloticase 35 Phase IIb 34 investigational drug 34 Acurox 34 StaphVAX 34 Phase III 34 Factive 34 ridaforolimus 34 investigational 34 Prolacria 34 European Medicines Agency 34 indiplon 33 VEGF Trap 33 Amigal 33 AzaSite 33 MK #A [001] 33 Krystexxa 33 pivotal Phase 33 Phase III trials 33 L MTP PE 33 hypoparathyroidism 32 Antegren 32 ceftobiprole 32 preclinical 32 Bepreve 32 BLA 31 Bronchitol 30 Probuphine 28 LibiGel 26 clinical trial